

## NEWSLETTER

- March 2022

### The inclusion is completed

A very good news for the trial is that we have included enough patients to conclude on the primary endpoint of the study. We stopped including patients 31.01.22 after a recommendation from the Data Monitoring Committee (DMC). Which means the study will be completed in Q1 2025.

We now have 466 patients randomized in total in the trial.

### Further plan

- Patients included will continue with study medication for a total of 3 years or until P.E is reached.
- Continue study visits of included patients (CT scan, CEA and QoL every 6 months).
- Complete eCRFs (all patients). Please make sure to enter missing data.
- Monitor will be doing final visits on all sites after the last patient has had their last study visit.

We will get back to you regarding collecting available tissue samples for molecular analysis.

### Study medication

All study nurses on each site now have access to allocate KIT-numbers from the new batch. A guide has been sent to every site.

Thank you all for your great effort in the study so far. If you have any questions, do not hesitate to contact us! We are available on both mail and phone.

The ASAC team

[www.asac.no](http://www.asac.no)

